var data={"title":"Pralidoxime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pralidoxime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6821?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pralidoxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pralidoxime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pralidoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pralidoxime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801639\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=9802\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212244\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Protopam Chloride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212264\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212248\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anticholinesterase overdose (eg, neostigmine, pyridostigmine):</b> IV: 1000-2000 mg; followed by increments of 250 mg every 5 minutes as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Organophosphate poisoning:</b> <b>Note:</b> Use in conjunction with atropine; a response to atropine should be established before pralidoxime is administered. IM or SubQ administration should be considered when IV administration is not feasible:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Loading dose: 1000-2000 mg; Maintenance: Repeat bolus of 1000-2000 mg after 1 hour and repeated every 10-12 hours thereafter, as needed. Alternatively, administer a loading dose of 30 mg/kg followed by a maintenance infusion of 8 mg/kg/hour (off-label dose; Roberts, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Mild symptoms:</i> 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1800 mg; may administer doses in rapid succession if severe symptoms develop</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Severe symptoms:</i> 600 mg; repeat twice in rapid succession to deliver a total dose of 1800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Persistent symptoms:</i> May repeat the entire series (1800 mg) beginning ~1 hour after administration of the last injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212258\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pralidoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pralidoxime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Organophosphate poisoning:</b> <b>Note:</b> Use in conjunction with atropine; a response to atropine should be established before pralidoxime is administered.  IM or SubQ administration should be considered when IV administration is not feasible:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents &le;16 years: Loading dose: 20-50 mg/kg (maximum: 2000 mg/dose); Maintenance infusion: 10-20 mg/kg/hour; alternatively, a repeat bolus of 20-50 mg/kg (maximum: 2000 mg/dose) may be administered after 1 hour and repeated every 10-12 hours thereafter, as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents &gt;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &lt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Mild symptoms:</i> 15 mg/kg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 45 mg/kg; may administer doses in rapid succession if severe symptoms develop</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Severe symptoms:</i> 15 mg/kg; repeat twice in rapid succession to deliver a total dose of 45 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Persistent symptoms:</i> May repeat the entire series (45 mg/kg) beginning ~1 hour after administration of the last injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;40 kg and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212249\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212250\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No specific dosage adjustment provided in manufacturer's labeling; however, because pralidoxime is excreted in the urine, dosage reduction is recommended in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20317636\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling; undergoes hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212224\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Intramuscular, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protopam Chloride: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212210\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212228\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Infuse as a 10-20 mg/mL solution over 15-30 minutes. Alternatively, if this is not practical or if pulmonary edema is present and/or fluid restriction is necessary, may administer as a 50 mg/mL solution by slow IV injection over &ge;5 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: Administer as a continuous or intermittent infusion at a rate not to exceed 200 mg/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, SubQ: May administer IM or SubQ if IV administration is not feasible. For pediatric patients, IM injection should be into the anterolateral aspect of the thigh. If using the auto-injector  (solution for IM injection), remove gray safety cap and place black end against outer thigh. Push hard until injector administers, hold in place for 10 seconds, then remove and massage area of injection. Auto-injector is intended for use by military personnel for self or buddy administration; may also be administered by qualified civilian emergency responders who have received adequate training on the recognition and treatment of nerve agent intoxication.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212227\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg, nerve agents); control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium, neostigmine, pyridostigmine) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212271\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pralidoxime may be confused with pramoxine, pyridoxine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protopam&reg; may be confused with protamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212216\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrest, hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, drowsiness, headache, paralysis, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Maculopapular rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT (transient), increased serum AST (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations, increased creatine phosphokinase, laryngospasm, muscle rigidity, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Abnormal accommodation, blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, hyperventilation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212231\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no absolute contraindications listed within the manufacturer&rsquo;s labeling. <b>Note:</b> According to the manufacturer, relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212214\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbamate poisoning: Pralidoxime is <b>not</b> indicated for the treatment of carbamate poisoning; acetylcholinesterase is weakly, but not permanently, affected by carbamates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; administration may precipitate a myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nonanticholinesterase poisoning: Pralidoxime is <b>not</b> indicated for the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Clinical symptoms that are consistent with suspected organophosphate poisoning (eg, organophosphate anticholinesterase pesticides and nerve agents) should be treated with the antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should include proper evacuation and decontamination procedures as indicated; medical personnel should protect themselves from inadvertent contamination. Antidote administration is intended only for initial management; definitive and more intensive medical care is required following administration. Individuals should not rely solely on antidote for treatment; the concomitant use of atropine will be necessary and other supportive measures (eg, artificial respiration) may still be required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299930\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212218\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9802&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212220\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13459587\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. A case report did not show evidence of adverse events after pralidoxime administration during the second trimester (Kamha, 2005). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20317518\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pralidoxime is excreted in breast milk. The manufacturer recommends that caution be exercised when administering pralidoxime to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212222\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry; cardiac monitor and blood pressure monitor required for IV administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212213\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reactivates cholinesterase that had been inactivated by phosphorylation due to exposure to organophosphate pesticides and cholinesterase-inhibiting nerve agents (eg, terrorism and chemical warfare agents such as sarin) by displacing the enzyme from its receptor sites; removes the phosphoryl group from the active site of the inactivated enzyme </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212230\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 0.6 to 2.7 L/kg; Severely poisoned pediatric patients (n=11; age: 0.8 to 18 years): ~9 L/kg (range: 1.7 to 13.8 L/kg) (Schexnayder 1998); may increase with increasing severity of organophosphate intoxication </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Apparent: 74 to 77 minutes; Poisoned patients (IM, IV): 3 to 4 hours; Pediatric patients (n=11; age: 0.8 to 18 years): 2.4 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IV: 5 to 15 minutes; IM: ~35 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% as metabolites and unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323722\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Protopam Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $104.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Pralidoxime Chloride Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/2 mL (2 mL): $39.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038776\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldopam (IN);</li>\n      <li>Contrathion (AR, BR, FR, GR, IT, TR);</li>\n      <li>Naprax (LK);</li>\n      <li>Neopam (LK);</li>\n      <li>Oridoxime (VN);</li>\n      <li>PAM (NZ);</li>\n      <li>Pam-A (SG, VN);</li>\n      <li>Pamcl (TW);</li>\n      <li>Pampara (MY, TW, VN);</li>\n      <li>Pamu (KR);</li>\n      <li>Pradox (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX,&rdquo; August, 2008. Available at <a href=\"http://www.atsdr.cdc.gov/mhmi/mmg166.pdf\" target=\"_blank\">http://www.atsdr.cdc.gov/mhmi/mmg166.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Kort WL, Kiestra SH, and Sangster B, &ldquo;The Use of Atropine and Oximes in Organophosphate Poisoning: A Modified Approach,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1988, 26(3-4):199-208. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/3418775/pubmed\" target=\"_blank\" id=\"3418775\">3418775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ekins BR and Geller RJ, &ldquo;Methomyl-Induced Carbamate Poisoning Treated With Pralidoxime Chloride,&rdquo; <i>West J Med</i>, 1994, 161(1):68-70. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/7941519/pubmed\" target=\"_blank\" id=\"7941519\">7941519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farrar HC, Wells TG, and Kearns GL, &ldquo;Use of Continuous Infusion of Pralidoxime for Treatment of Organophosphate Poisoning in Children,&rdquo; <i>J Pediatr</i>, 1990, 116(4):658-61. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/2319410/pubmed\" target=\"_blank\" id=\"2319410\">2319410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jovanovic D, &ldquo;Pharmacokinetics of Pralidoxime Chloride. A Comparative Study in Healthy Volunteers and in Organophosphorus Poisoning,&rdquo; <i>Arch Toxicol</i>, 1989, 63(5):416-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/2818204/pubmed\" target=\"_blank\" id=\"2818204\">2818204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamha AA, Al Omary IY, Zalabany HA, et al, &quot;Organophosphate Poisoning in Pregnancy: A Case Report,&quot; <i>Basic Clin Pharmacol Toxicol</i>, 2005, 96(5):397-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/15853933/pubmed\" target=\"_blank\" id=\"15853933\">15853933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurtz PH, &ldquo;Pralidoxime in the Treatment of Carbamate Intoxication,&rdquo; <i>Am J Emerg Med</i>, 1990, 8(1):68-70. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/2403479/pubmed\" target=\"_blank\" id=\"2403479\">2403479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Medical Management Guidelines (MMGs) for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX.&rdquo; Available at  <a href=\"http://www.atsdr.cdc.gov/mmg/mmg.asp?id=523&amp;tid=93\" target=\"_blank\">http://www.atsdr.cdc.gov/mmg/mmg.asp?id=523&amp;tid=93</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medicis JJ, Stork CM, Hoffman RS, et al, &ldquo;Improved 2-PAM Dosing Regimen in Human Volunteers: A Pharmacokinetic Study,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36:377. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy M and Desai H, &ldquo;Pralidoxime-Induced Laryngospasm,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36:375.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts DM and Aaron CK, &ldquo;Management of  Acute Organophosphorus Pesticide Poisoning,&rdquo; <i>BMJ</i>, 2007, 334(7594):629-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/17379909/pubmed\" target=\"_blank\" id=\"17379909\">17379909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rotenberg JS and Newmark J, &quot;Nerve Agent Attacks on Children: Diagnosis and Management,&quot; <i>Pediatrics</i>, 2003, 112(3 Pt 1):648-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/12949297/pubmed\" target=\"_blank\" id=\"12949297\">12949297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schexnayder S, James LP, Kearns GL, et al, &ldquo;The Pharmacokinetics of Continuous Infusion Pralidoxime in Children With Organophosphate Poisoning,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36(6):549-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-drug-information/abstract-text/9776957/pubmed\" target=\"_blank\" id=\"9776957\">9776957</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9802 Version 87.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F22801639\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212244\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F212264\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F212248\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F212258\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F212249\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F212250\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20317636\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212224\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F212210\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F212228\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F212227\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212271\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212216\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212231\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212214\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299930\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212218\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212220\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13459587\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20317518\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F212222\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F212213\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F212230\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323722\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038776\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9802|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pralidoxime-patient-drug-information\" class=\"drug drug_patient\">Pralidoxime: Patient drug information</a></li><li><a href=\"topic.htm?path=pralidoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Pralidoxime: Pediatric drug information</a></li></ul></div></div>","javascript":null}